Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Microdose Cocktail in Diabetic Patients
NCT06273215Phase 4Recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Mar 2023
- Primary completion
- Dec 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label trial of midazolam, dabigatran, pitavastatin, atorvastatin and rosuvastatin in type 1 diabetes mellitus (T1D) and type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Peking University Third Hospital. Primary endpoint: Pharmacokinetics of study drug at 24 hours. Started Mar 2023; status: recruiting.
02
Drugs
midazolamdabigatranpitavastatinatorvastatinrosuvastatin
03
Conditions
type 1 diabetes mellitus (T1D)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06273215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06273215.